Tasigna (nilotinib) is a pharmaceutical medication commonly utilized to deal with Philadelphia chromosome-positive chronic myeloid leukemia.

Novartis International AG, the Swiss pharmaceutical firm accountable for manufacturing and advertising Tasigna, was aware of the danger for Tasigna atherosclerosis because at least 2011 but stayed quiet.

Novartis issued a Tasigna unwanted effects warning in Canada in 2013 in combination with the Canadian health assistance, but not warned physicians or sufferers in the USA. To know about Tasigna lawsuit you can browse to Tasigna Atherosclerosis Attorneys Handling National Tasigna Lawsuits.

Tasigna Atherosclerosis Warning

Novartis participated in an aggressive marketing and advertising campaign aimed at boosting Tasigna more than rival leukemia treatments, touting false promises of this drug’s excellence and omitting Tasigna atherosclerosis warning advice. Tasigna is one of the ten hottest cancer drugs from the world, yielding over $1.7 billion in earnings in 2016.

In the event that you or a loved one has suffered from Tasigna unwanted effects or complications, then you could qualify to get reimbursement by submitting Tasigna litigation.

These Tasigna attorneys offer complimentary, no-obligation example reviews to individuals and household members that match this description.

Our Tasigna attorneys have a solid history of success from the domain of dangerous drug litigation. In the event you decide to keep our Tasigna attorneys, there’s never any charge unless we win compensation for your benefit.